Market segments covered by this report include tissue engineering and cell transplantation products for the treatment of neurologic diseases/disorders including Alzheimer's disease, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease, peripheral nerve regeneration, spinal cord injury, and stroke. A variety of tissue engineering approaches show promise for treating diseases and disorders of the central nervous system, and many companies are developing product candidates for the U.S. market based on several technologies including gene therapy, growth factors, monoclonal antibodies, nerve grafting, and stem cells.
In addition, this report includes an overview of some of the most prevalent neurologic disorders and diseases in the U.S. as well as an analysis of emerging competitors and products/technologies that currently are under development.
This Medtech Insight report is the third in a series of reports covering U.S. tissue engineering markets. Upcoming reports in this series will provide analyses of U.S. markets for tissue-engineered products for organ regeneration, skin replacement, and urology applications.
EXECUTIVE SUMMARY i. The Nervous System ii. Neurologic and Other Diseases/Disorders a. Alzheimer's Disease b. Amyotrophic Lateral Sclerosis c. Epilepsy d. Multiple Sclerosis e. Parkinson's Diseases f. Stroke iii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iv. Current and Emerging Markets for Neurologic Tissue Engineering and Cell Transplantation Products a. Gene Therapy b. Growth Factors c. Nerve Grafting d. Stem Cell-Based Therapies e. Other Tissue Engineering Technologies f. Market Analysis v. Methodology Exhibit ES-1: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019 1. OVERVIEW OF THE NERVOUS SYSTEM AND SELECTED NEUROLOGIC DISEASES/DISORDERS 1.1 The Nervous System 1.1.1 Sacral Nerves 1.1.2 Vagus Nerves 1.1.3 Neurons 1.1.4 The Brain 1.1.5 The Spine 1.2 Neurologic and Other Diseases/Disorders 1.2.1 Alzheimer's Disease 22.214.171.124 Etiology 126.96.36.199 Epidemiology 1.2.2 Amyotrophic Lateral Sclerosis 188.8.131.52 Etiology 184.108.40.206 Epidemiology 1.2.3 Epilepsy 220.127.116.11 Etiology 18.104.22.168 Epidemiology 1.2.4 Multiple Sclerosis 22.214.171.124 Etiology 126.96.36.199 Epidemiology 1.2.5 Parkinson's Disease 188.8.131.52 Etiology 184.108.40.206 Epidemiology 1.2.6 Stroke 220.127.116.11 Etiology 18.104.22.168 Epidemiology Exhibit 1-1: United States Population, by Age Group, Selected Years, 2000-2050 Exhibit 1-2: The Sacral Nervous System Exhibit 1-3: The Vagus Nerve Exhibit 1-4: Anatomy of the Brain Exhibit 1-5: Anatomy of a Spinal Segment Exhibit 1-6: Alzheimer's Disease, Facts and Figures Exhibit 1-7: Amyotrophic Lateral Sclerosis, Facts and Figures Exhibit 1-8: Epilepsy, Facts and Figures Exhibit 1-9: Multiple Sclerosis, Facts and Figures Exhibit 1-10: Parkinson's Disease, Facts and Figures Exhibit 1-11: Stroke, Facts and Figures 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 22.214.171.124 Collagen 126.96.36.199 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 188.8.131.52 Deoxyribonucleic Acid Transfection Vectors 184.108.40.206 Genetically Manipulated Cells 220.127.116.11 Three-Dimensional Polymer Technology 18.104.22.168 Transgenics 22.214.171.124 Fibroblasts 126.96.36.199 Immortalized Neural Stem Cells 188.8.131.52 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 184.108.40.206 Flatbed Perfusion Systems 220.127.116.11 Hollow Fiber Bioreactor Systems 18.104.22.168 Cell Suspension Systems 22.214.171.124 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. CURRENT AND EMERGING MARKETS FOR NEUROLOGIC TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS 3.1 Gene Therapy 3.1.1 Ceregene 3.1.2 Genzyme 3.1.3 Isis Pharmaceuticals 3.2 Growth Factors 3.2.1 Acorda Therapeutics 3.2.2 Alseres Pharmaceuticals 3.2.3 NeuroNova in collaboration with Medtronic 3.2.4 The Parkinson Study Group 3.3 Nerve Grafting 3.3.1 AxoGen 3.3.2 Integra LifeSciences 3.4 Peptides 3.4.1 CellMed/Biocompatibles International 3.5 Remyelinating Monoclonal Antibodies 3.5.1 Acorda Therapeutics 3.6 Stem Cell-Based Therapies 3.6.1 Human Adult Stem Cells 126.96.36.199 BrainStorm Cell Therapeutics 188.8.131.52 NeuroNova 184.108.40.206 ReNeuron 3.6.2 Human Embryonic Stem Cells 220.127.116.11 Geron 3.6.3 Fetal Neural Stem Cells 18.104.22.168 Neuralstem 22.214.171.124 StemCells 3.6.4 Fetal Porcine Cells 3.6.5 Nasal Cavity-Derived Stem Cells 3.6.6 Skin-Derived Stem Cells 3.7 Retinal Pigmented Epithelial Cell Transplants 3.7.1 Titan Pharmaceuticals in collaboration with Bayer 3.8 Market Analysis 3.8.1 Market Drivers 3.8.2 Market Limiters 3.9 Competitive Analysis Exhibit 3-1: 2010, Selected Tissue-Engineered/Regeneration Products for Neurology Applications Exhibit 3-2: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-3: Technologies for Neurologic Tissue Engineering, by Indication, 2009 and 2019 Exhibit 3-4: Technologies for Tissue Engineering and Cell Transplantation, Product Introduction Forecast, by Indication, 2014 and 2019 4. COMPANY PROFILES 4.1 Acorda Therapeutics, Inc. 4.2 AxoGen, Inc. 4.3 Ceregene, Inc. 4.4 Genzyme Corporation 4.5 Geron Corporation 4.6 Integra LifeSciences Corporation 4.7 Isis Pharmaceuticals, Inc. 4.8 Neuralstem, Inc. 4.9 NeuroNova AB 4.10 ReNeuron Group PLC APPENDIX: COMPANY LISTING